Segall Bryant & Hamill LLC purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 18,968 shares of the company's stock, valued at approximately $921,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter worth about $55,000. Blue Trust Inc. increased its position in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the period. Asset Management One Co. Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after buying an additional 301 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.
In related news, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now owns 118,388 shares in the company, valued at approximately $5,724,059.80. The trade was a 3.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the company's stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now directly owns 75,409 shares of the company's stock, valued at approximately $3,504,256.23. This trade represents a 3.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,533 shares of company stock worth $1,571,652 over the last three months. 27.10% of the stock is owned by insiders.
AMPH stock opened at $45.46 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 0.89 and a beta of 0.82. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The business has a fifty day simple moving average of $48.26 and a 200-day simple moving average of $44.44.
A number of research firms have recently weighed in on AMPH. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday. They issued an "equal weight" rating and a $55.00 price objective for the company. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and an average price target of $60.33.
Read Our Latest Report on AMPH
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.